Evidence map›Paper›PMID 35110975›Full record

ArticleDose-response : a publication of International Hormesis Society

Mesoporous SBA-15 Silica-Loaded Nano-formulation of Quercetin: A Probable Radio-Sensitizer for Lung Carcinoma.

Saad Alkahtani, Saud Alarifi, Nada H Aljarba, Hamzah A Alghamdi, Abdullah A Alkahtane

Open access · goldAbstract read
In one paragraph

Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Saad AlkahtaniDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-7381-5110
Saud AlarifiDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-3613-5228
Nada H AljarbaDepartment of Biology, College of Sciences, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Hamzah A AlghamdiDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Abdullah A AlkahtaneDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
King Saud University · SAPrincess Nourah bint Abdulrahman University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is considered as one of the most serious disease worldwide. The progress of drug carriers based on nonmaterial, which selectively hold chemotherapeutic agents to cancer cells, has become a major focus in biomedical research. This study aimed to evaluate the growth inhibition and apoptosis induction of the human lung cancer cells (A-549) by Q-loaded SBA-15 conjugate system. Mesoporous silica nanoparticles (SBA-15) as host materials for transporting therapeutics medicaments were fabricated for targeted drug delivery toward lung cancer. With the objective of increasing bioavailability and aqueous solubility of flavonoids, SBA-15 was successfully loaded with the quercetin (Q)-a major flavonoid and characterized with the help of Fourier-transform infrared spectroscopy (FTIR) and transmission electron microscopy (TEM). The biological investigation on A549 cell line confirmed that the efficacy of Q-SBA-15 is much higher than only Q. Moreover, the apoptotic pathway of synthesized Q-SBA-15 NPs examined that the Q-SBA-15-mediated apoptosis

Indexed as

apoptosislung cancermesoporousnanoparticlesquercetin

Identifiers

PMID35110975
PMCPMC8777362
OpenAlexW4205442533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.